Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
rosacea eczema alopecia ceramide keratosis pityriasis basal cell melanoma keratosis purpuraYour Article Summary
See Latest ArticlesInfliximab in the treatment of plaque type psoriasis
Clinical, Cosmetic and Investigational Dermatology, 05/01/09
Saraceno R et al. - Psoriasis is a chronic and immunomediated skin disease characterized by erythematous scaly plaques. Psoriasis affects approximately 1% to 3% of the Caucasian population. Tumor necrosis factor alpha is a proinflammatory cytokine that plays a critical role in the pathogenesis of psoriasis. Infliximab is an anti-TNF-alpha drug widely used for the treatment of plaque type psoriasis and psoriatic arthritis.
Related Articles
Pediatric psoriasis: an update
Therapeutics and Clinical Risk Management, 10/22/09
Relevance Score: 95%
FDA Approves New Drug to Treat Psoriasis
Internet Source, 11/02/09
Relevance Score: 91%
Study shows major burden of psoriasis
Internet Source, 10/29/09
Relevance Score: 91%
Prevalence of myocardial infarction in patients with psoriasis in central China
Journal of the European Academy of Dermatology and Venereology, 10/27/09
Relevance Score: 91%
Why nail psoriasis remains difficult to treat
Dermatology in Practice, 10/12/09
Relevance Score: 91%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
A case of atopic dermatitis-associated lichen amyloidosis successfully treated with oral cyclosporine and narrow band UVB therapy in succession
Journal of Dermatological Treatment , 12/10/09
Muscle Weakness After Repeated Injection of Botulinum Toxin Type A Evaluated According to Bite Force Measurement of Human Masseter Muscle
Dermatologic Surgery, 12/10/09
Randomized, Placebo-Controlled Study of a New Botulinum Toxin Type A for Treatment of Glabellar Lines: Efficacy and Safety
Dermatologic Surgery, 12/10/09
Today in Psoriasis...keeping you current
Receive free subspecialty "5-minute updates" via email
Comorbidities in Patients with Psoriasis
American Journal of Medicine, 12/09/09
Site of psoriasis (scalp or intergluteal/perianal), >=3 affected sites, and nail dystrophy predicted psoriatic arthritis in incident psoriasis
Evidence-Based Medicine, 12/08/09
Efficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial
Archives of Drug Information, 12/08/09
Sponsor
Article Search
Sponsor